HYPERANDROGENISM AND INSULIN RESISTANCE IN WOMEN

女性雄激素过多症和胰岛素抵抗

基本信息

  • 批准号:
    3325255
  • 负责人:
  • 金额:
    $ 14.32万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1988
  • 资助国家:
    美国
  • 起止时间:
    1988-07-01 至 1991-06-30
  • 项目状态:
    已结题

项目摘要

Ovarian hyperandrogenism is one of the most common endocrinopathies of reproductive age women. Proposed etiologic mechanisms for this common clinical syndrome include primary abnormalities of the hypothalamic-pituitary unit, the ovary and the adrenal gland. A unique opportunity to identify a specific molecular cause of ovarian hyperandrogenism is provided by the observation that hyperinsulinemia is commonly associated with hyperandrogenism. The objective of this proposal is to test the hypothesis that insulin and insulin-like growth factors (IGFs) regulate ovarian androgen production and metabolism in women. Preliminary evidence indicates that insulin, IGF-1 and LH stimulate androgen production in incubations of minced human ovarian stroma and theca. To further explore these effects the following experiments are planned: 1) determination of detailed dose-response curves for insulin, IGF-1 and LH stimulation of thecal and stomal androgen production, 2) determination of the effects of insulin, IGF-1 and LH on androgen production in theca obtained from healthy or atretic follicles, 3) analysis of the binding characteristics of insulin and IGFs to insulin receptors, and IGF-1 receptors in ovarian theca and stroma, 4) analysis of the effects of insulin and IGFs on specific enzymes of thecal androgen biosynthesis (e.g. 17B - hydroxysteroid dehydrogenase), 5) use dot blots to probe ovarian tissue for the presence of mRNA for the insulin and IGF-1 receptors. Preliminary evidence indicated that the oral administration of 100 gms of glucose to hyperinsulinemic-hyperandrogenic women produces an acute rise in serum androstenedione, testosterone and dihydrotestosterone. To test the effects of insulin and glucose on circulating androstenedione and testosterone, the following experiments are planned: 1) examine the effects of 50 gm, 100 gm and 200 gm or oral glucose; and 25 gm and 50 gm of intravenous glucose on circulating insulin and androgens, 2) directly test the effects of hyperinsulinemia on circulating insulin by using a euglycemic clamp; and 3) directly test the effects of hyperglycemia on circulating androgens by using a hyperglycemic clamp. These experiments should yield important information concerning the role of metabolic factors in the regulation of ovarian androgen production and metabolism.
卵巢雄激素过多症是最常见的一种

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Robert L Barbieri其他文献

Nonhormonal medication treatment of VMS
VMS 的非激素药物治疗
  • DOI:
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Robert L Barbieri
  • 通讯作者:
    Robert L Barbieri
Medication treatment of opioid use disorder in primary care practice: Opportunities and limitations
初级保健实践中阿片类药物使用障碍的药物治疗:机遇和局限性
  • DOI:
    10.12788/obgm.0308
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Robert L Barbieri
  • 通讯作者:
    Robert L Barbieri
The clinical utility of newly approved angiogenic markers for identifying patients at risk for adverse outcomes due to preeclampsia
新批准的血管生成标记物在识别因先兆子痫导致不良结果风险的患者方面的临床应用
  • DOI:
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Robert L Barbieri
  • 通讯作者:
    Robert L Barbieri
Breakthroughs in the prevention of RSV disease among infants
预防婴儿 RSV 疾病的突破
  • DOI:
    10.12788/obgm.0323
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Robert L Barbieri
  • 通讯作者:
    Robert L Barbieri
Anti-obesity medications: Breakthroughs and limitations
抗肥胖药物:突破和局限性
  • DOI:
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Robert L Barbieri
  • 通讯作者:
    Robert L Barbieri

Robert L Barbieri的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Robert L Barbieri', 18)}}的其他基金

Development of Scholars in Ob-Gyn for the 21th Century
21世纪妇产科学者的发展
  • 批准号:
    6937579
  • 财政年份:
    1999
  • 资助金额:
    $ 14.32万
  • 项目类别:
Development of Scholars in Ob-Gyn for the 21th Century
21世纪妇产科学者的发展
  • 批准号:
    7059471
  • 财政年份:
    1999
  • 资助金额:
    $ 14.32万
  • 项目类别:
DEVELOPMENT OF SCHOLARS IN OB-GYN FOR THE 21ST CENTURY
21世纪妇产科学者的发展
  • 批准号:
    6689584
  • 财政年份:
    1999
  • 资助金额:
    $ 14.32万
  • 项目类别:
Development of Scholars in Ob-Gyn for the 21th Century
21世纪妇产科学者的发展
  • 批准号:
    7631424
  • 财政年份:
    1999
  • 资助金额:
    $ 14.32万
  • 项目类别:
DEVELOPMENT OF SCHOLARS IN OB-GYN FOR THE 21ST CENTURY
21世纪妇产科学者的发展
  • 批准号:
    6329782
  • 财政年份:
    1999
  • 资助金额:
    $ 14.32万
  • 项目类别:
Development of Scholars in Ob-Gyn for the 21th Century
21世纪妇产科学者的发展
  • 批准号:
    7243341
  • 财政年份:
    1999
  • 资助金额:
    $ 14.32万
  • 项目类别:
Development of Scholars in Ob-Gyn for the 21th Century
21世纪妇产科学者的发展
  • 批准号:
    7417418
  • 财政年份:
    1999
  • 资助金额:
    $ 14.32万
  • 项目类别:
DEVELOPMENT OF SCHOLARS IN OB-GYN FOR THE 21ST CENTURY
21世纪妇产科学者的发展
  • 批准号:
    6476582
  • 财政年份:
    1999
  • 资助金额:
    $ 14.32万
  • 项目类别:
DEVELOPMENT OF SCHOLARS IN OB-GYN FOR THE 21ST CENTURY
21世纪妇产科学者的发展
  • 批准号:
    6024024
  • 财政年份:
    1999
  • 资助金额:
    $ 14.32万
  • 项目类别:
DEVELOPMENT OF SCHOLARS IN OB-GYN FOR THE 21ST CENTURY
21世纪妇产科学者的发展
  • 批准号:
    6625124
  • 财政年份:
    1999
  • 资助金额:
    $ 14.32万
  • 项目类别:

相似海外基金

DIETARY SUPPLEMENT ANDROSTENEDIONE AND HORMONE LEVELS IN HEALTHY MEN
健康男性膳食补充剂雄烯二酮和激素水平
  • 批准号:
    6586382
  • 财政年份:
    2002
  • 资助金额:
    $ 14.32万
  • 项目类别:
DIETARY SUPPLEMENT ANDROSTENEDIONE AND HORMONE LEVELS IN HEALTHY MEN
健康男性膳食补充剂雄烯二酮和激素水平
  • 批准号:
    6574349
  • 财政年份:
    2001
  • 资助金额:
    $ 14.32万
  • 项目类别:
DIETARY SUPPLEMENT ANDROSTENEDIONE AND HORMONE LEVELS IN HEALTHY MEN
健康男性膳食补充剂雄烯二酮和激素水平
  • 批准号:
    6505152
  • 财政年份:
    2000
  • 资助金额:
    $ 14.32万
  • 项目类别:
DIETARY SUPPLEMENT ANDROSTENEDIONE AND HORMONE LEVELS IN HEALTHY MEN
健康男性膳食补充剂雄烯二酮和激素水平
  • 批准号:
    6308034
  • 财政年份:
    1999
  • 资助金额:
    $ 14.32万
  • 项目类别:
DIETARY SUPPLEMENT ANDROSTENEDIONE AND HORMONE LEVELS IN HEALTHY MEN
健康男性膳食补充剂雄烯二酮和激素水平
  • 批准号:
    6265475
  • 财政年份:
    1998
  • 资助金额:
    $ 14.32万
  • 项目类别:
DIETARY SUPPLEMENT ANDROSTENEDIONE AND HORMONE LEVELS IN HEALTHY MEN
健康男性膳食补充剂雄烯二酮和激素水平
  • 批准号:
    6297936
  • 财政年份:
    1998
  • 资助金额:
    $ 14.32万
  • 项目类别:
DIETARY SUPPLEMENT ANDROSTENEDIONE AND HORMONE LEVELS IN HEALTHY MEN
健康男性膳食补充剂雄烯二酮和激素水平
  • 批准号:
    6297852
  • 财政年份:
    1998
  • 资助金额:
    $ 14.32万
  • 项目类别:
ANDROSTENEDIONE INCREASES ESTRADIOL LEVELS BUT NOT PRETERM LABOR
雄烯二酮会增加雌二醇水平,但不会增加早产
  • 批准号:
    6247230
  • 财政年份:
    1997
  • 资助金额:
    $ 14.32万
  • 项目类别:
EFFECT OF DIETARY SUPPLEMENT ANDROSTENEDIONE ON HORMONE LEVELS IN HEALTHY MEN
膳食补充剂雄烯二酮对健康男性激素水平的影响
  • 批准号:
    6286470
  • 财政年份:
    1978
  • 资助金额:
    $ 14.32万
  • 项目类别:
DISCRIMINATION OF OVARIAN VS ADRENAL ANDROSTENEDIONE
卵巢雄烯二酮与肾上腺雄烯二酮的区别
  • 批准号:
    3975067
  • 财政年份:
  • 资助金额:
    $ 14.32万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了